CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,310,688 | -19.3% | 94,970 | -0.2% | 0.25% | -17.1% |
| Q2 2023 | $5,341,833 | +27.6% | 95,152 | +2.8% | 0.30% | +19.1% |
| Q1 2023 | $4,185,313 | +31.5% | 92,534 | +18.2% | 0.25% | +14.6% |
| Q4 2022 | $3,182,895 | -36.0% | 78,300 | +2.9% | 0.22% | -36.9% |
| Q3 2022 | $4,972,000 | +69.9% | 76,085 | +58.0% | 0.35% | +57.7% |
| Q2 2022 | $2,926,000 | +7.8% | 48,149 | +11.4% | 0.22% | +41.9% |
| Q1 2022 | $2,714,000 | -17.2% | 43,237 | 0.0% | 0.16% | -6.6% |
| Q4 2021 | $3,276,000 | -27.6% | 43,237 | +7.0% | 0.17% | -32.5% |
| Q3 2021 | $4,522,000 | -30.1% | 40,399 | +1.1% | 0.25% | -30.9% |
| Q2 2021 | $6,467,000 | +19.5% | 39,947 | -10.0% | 0.36% | +8.9% |
| Q1 2021 | $5,410,000 | -49.0% | 44,398 | -36.0% | 0.33% | -47.3% |
| Q4 2020 | $10,618,000 | +85.5% | 69,349 | +1.3% | 0.62% | +59.8% |
| Q3 2020 | $5,724,000 | – | 68,433 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |